Expert Weighs in on Future of CAR T-Cell Therapy Treatment Directions
Kelly L. Garvin, BSN, RN, OCN, discusses what changes she hopes to see in CAR T-Cell therapy treatment over the coming years.
Oncology Nurses Who Proactively Manage CAR T-Cell Therapy-Related AEs Can Ensure Their Patients Remain on Treatment
Proper training can help oncology nurses act as intensivists and quickly identify if their patients are experiencing any CAR T-cell therapy-related adverse events.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
